Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

Recent evidence suggests that inhibition of bromodomain and extra-terminal (BET) epigenetic readers may have clinical utility against acute myeloid leukemia (AML). Here we validate this hypothesis, demonstrating the efficacy of the BET inhibitor I-BET151 across a variety of AML subtypes driven by di...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, M A, Gudgin, E J, Horton, S J, Giotopoulos, G, Meduri, E, Robson, S, Cannizzaro, E, Osaki, H, Wiese, M, Putwain, S, Fong, C Y, Grove, C, Craig, J, Dittmann, A, Lugo, D, Jeffrey, P, Drewes, G, Lee, K, Bullinger, L, Prinjha, R K, Kouzarides, T, Vassiliou, G S, Huntly, B J P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918873/
https://www.ncbi.nlm.nih.gov/pubmed/24220271
http://dx.doi.org/10.1038/leu.2013.338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918873/
https://www.ncbi.nlm.nih.gov/pubmed/24220271
http://dx.doi.org/10.1038/leu.2013.338

Ejemplares similares